Tourmaline Bio (TRML) is hosting its Investor Day. Tourmaline today is announcing the over-enrollment of its Phase 2 TRANQUILITY trial, which evaluates quarterly and monthly subcutaneous dosing of pacibekitug in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease. Tourmaline expects to report topline data from this trial in the second quarter of 2025. Expansion of Cardiovascular Scientific Advisory Board, SAB, with two new appointments: Deepak L. Bhatt; Dipender Gill.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.